Wells Fargo raised the firm’s price target on Veeva (VEEV) to $326 from $300 and keeps an Overweight rating on the shares. The firm believes investor sentiment is “incrementally cautious” into the company’s fiscal Q2 report while the company’s guidance is low enough to generate a beat. Veeva’s “solid” business momentum seems little changed from the prior quarter, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VEEV:
- Veeva highlights GSK Vault CRM go-live across Europe
- GSK Vault CRM rollout a ‘key milestone’ for Veeva, says Raymond James
- Options Volatility and Implied Earnings Moves This Week, August 25 – August 29, 2025
- VEEV Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Cautious Outlook on Veeva Systems Amid Growth Sustainability Concerns and Sector Risks